PXN and heart failure: Moreover, injection of a second, independent splice site targeting MO (MO2-paxillin) led to a similar heart failure phenotype as injection of MO1-paxillin, 82.27% ± 7.9% of MO2-paxillin injected embryos developed contractile dysfunction, whereas only 9.5% ± 2.6% of control-injected embryos showed a comparable phenotype (S2E–S2G Fig).